Literature DB >> 6521989

Vitreous hemorrhage after vitrectomy for diabetic retinopathy.

M A Novak, T A Rice, R G Michels, C Auer.   

Abstract

The records of 596 consecutive vitrectomy cases performed for complications of diabetic retinopathy were reviewed to determine the incidence of intraoperative and postoperative vitreous hemorrhage and to determine if blood cleared more rapidly in aphakic compared to phakic eyes. Uncontrollable intraocular bleeding occurred in two eyes (0.5%). Vitreous hemorrhage was present on the first postoperative day in 278 eyes (63%). This early hemorrhage cleared in an average of 9.1 weeks in phakic eyes and 3.4 weeks in aphakic eyes. Further vitreous hemorrhage occurred in 88 eyes (23%). Sixty-four percent of later hemorrhages occurred in 88 eyes (23%). Sixty-four percent of later hemorrhages occurred within six months of the operation and 80% occurred within one year. Later vitreous hemorrhage cleared in an average of 16.2 weeks in phakic eyes and 5.3 weeks in aphakic eyes. Of the 311 eyes with vitreous hemorrhage at some time during the postoperative course, twenty-nine eyes (9%) underwent reoperation to remove nonclearing blood. Nonclearing vitreous hemorrhage was the main cause of final visual loss in only 15 (3.4%) of 438 eyes with adequate follow-up, and 6 of these 15 eyes had final vision of 5/200 or better.

Entities:  

Mesh:

Year:  1984        PMID: 6521989     DOI: 10.1016/s0161-6420(84)34099-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  34 in total

1.  Macular morphologic findings on optical coherence tomography after microincision vitrectomy for proliferative diabetic retinopathy.

Authors:  Tomoaki Murakami; Akihito Uji; Ken Ogino; Noriyuki Unoki; Shin Yoshitake; Yoko Dodo; Takahiro Horii; Kazuaki Nishijima; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2015-05-09       Impact factor: 2.447

Review 2.  The pars plana incision: experimental studies, pathologic observations, and clinical experience.

Authors:  A E Krieger
Journal:  Trans Am Ophthalmol Soc       Date:  1991

3.  Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.

Authors:  Dong Ho Park; Jae Pil Shin; Si Yeol Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-12       Impact factor: 3.117

Review 4.  Antiplatelets and anticoagulants in vitreoretinal surgery, with a special emphasis on novel anticoagulants: a national survey and review.

Authors:  Rupa Patel; Stephen Charles; Assad Jalil
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-18       Impact factor: 3.117

5.  Perfluorocarbon in vitreoretinal surgery and preoperative bevacizumab in diabetic tractional retinal detachment.

Authors:  J Fernando Arevalo; Martin A Serrano; Juan D Arias
Journal:  World J Diabetes       Date:  2014-10-15

6.  Cryoapplication in diabetic retinopathy.

Authors:  A S Lim; B C Ang
Journal:  Int Ophthalmol       Date:  1986-05       Impact factor: 2.031

7.  Fibrovascular ingrowth and recurrent haemorrhage following diabetic vitrectomy.

Authors:  J F West; Z J Gregor
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

Review 8.  Current management of vitreous hemorrhage due to proliferative diabetic retinopathy.

Authors:  Jaafar El Annan; Petros E Carvounis
Journal:  Int Ophthalmol Clin       Date:  2014

9.  Cryotherapy of sclerotomy sites for prevention of late post-vitrectomy diabetic hemorrhage: a randomized clinical trial.

Authors:  Morteza Entezari; Alireza Ramezani; Hamid Ahmadieh; Pejman Bakhtiari; Mehdi Yaseri; Kian Soltani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-25       Impact factor: 3.117

10.  Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy.

Authors:  Ashraf M El-Batarny
Journal:  Clin Ophthalmol       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.